InflaRx N.V. (NASDAQ:IFRX) Short Interest Up 26.7% in December

InflaRx N.V. (NASDAQ:IFRX) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 2,745,086 shares, an increase of 26.7% from the November 30th total of 2,166,680 shares. Currently, 4.9% of the company’s stock are sold short. Based on an average daily volume of 847,910 shares, the days-to-cover ratio is currently 3.2 days. Based on an average daily volume of 847,910 shares, the days-to-cover ratio is currently 3.2 days. Currently, 4.9% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IFRX shares. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research note on Wednesday. Wall Street Zen downgraded InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of InflaRx in a research report on Tuesday. Guggenheim boosted their price target on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, InflaRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

InflaRx Trading Down 1.0%

NASDAQ IFRX traded down $0.01 during trading hours on Thursday, reaching $1.01. The company’s stock had a trading volume of 595,574 shares, compared to its average volume of 718,217. The business has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $1.13. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.77. The stock has a market cap of $67.80 million, a PE ratio of -1.49 and a beta of 1.46.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Monday, November 10th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts predict that InflaRx will post -1.04 EPS for the current year.

Institutional Investors Weigh In On InflaRx

A number of hedge funds have recently added to or reduced their stakes in IFRX. Cubist Systematic Strategies LLC grew its position in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC raised its holdings in shares of InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after buying an additional 17,056 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of InflaRx by 29.1% during the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after buying an additional 42,489 shares during the period. Concurrent Investment Advisors LLC acquired a new position in shares of InflaRx during the second quarter worth approximately $65,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after buying an additional 91,927 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.